Welcome to our dedicated page for Glaukos SEC filings (Ticker: GKOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Glaukos Corporation filings document the regulatory record for an ophthalmic pharmaceutical and medical technology company with common stock listed on the New York Stock Exchange under GKOS. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary net sales information, supplemental business summaries, and Regulation FD investor presentations.
The company’s proxy materials provide governance and executive-compensation disclosures, including equity-award and pay-versus-performance information. These filings also identify Glaukos as a Delaware corporation and frame disclosure around its glaucoma, corneal-disorder, and retinal-disease therapies, commercial products, risk disclosures, and public-company reporting obligations.
Glaukos Corp reported that its President and COO acquired 7,316 stock options on 12/11/2025 under a previously granted award tied to pre-determined operational targets. These options have an exercise price of $55.18 and were earned after the Compensation, Nominating & Governance Committee determined that certain operational targets over a multi-year performance period had been achieved.
The options represent a portion of an award originally granted on March 24, 2022, and will vest in two equal installments, with 50% becoming exercisable in March 2026 and the remaining 50% in December 2026. Following this transaction, the executive beneficially owned 65,013 derivative securities, held directly.
Glaukos Corporation disclosed that its senior vice president and chief financial officer earned 3,660 stock options tied to performance goals. These options, with an exercise price of $55.18 per share, are part of an award originally granted in March 2022 and became earned after the company met specified operational targets.
Half of this earned portion will vest and become exercisable in March 2026, with the remaining half vesting in December 2026. After this update and a de minimis correction of a prior mathematical error, the officer directly holds 37,510 stock options in total.
Glaukos Corporation’s Chief Development Officer reported an equity award update. On December 11, 2025, the officer was credited with 2,054 shares of common stock at a price of $0, tied to a previously granted restricted stock unit (RSU) award from March 24, 2022 that depended on meeting pre-set operational targets over a multi-year period.
The board’s Compensation, Nominating and Governance Committee determined that certain of these targets had been achieved, and this share amount represents the portion of the award earned based on that performance. Half of these shares will vest and be delivered in March 2026, with the remaining half vesting and delivering in December 2026. After this update, the officer beneficially owns 77,961 shares, including 44,589 RSUs that are still unvested.
Glaukos Corp (GKOS) director transaction: On 12/09/2025, a director exercised a stock option to acquire 5,000 shares of common stock at an exercise price of $24.69 per share, then sold 5,000 shares of common stock on the same date at a weighted average price of $107.27 per share across multiple trades.
After these transactions, the director beneficially owns 34,905 shares of Glaukos common stock, which includes 2,569 restricted stock units that have not yet vested or been delivered, as well as vested units with deferred delivery. The director also continues to hold 10,000 stock options with an exercise price of $24.69, originally granted in 2016 and already fully vested.
Glaukos Corporation insider has filed notice of a planned sale of common stock under Rule 144. The seller plans to sell 5,000 shares of Glaukos common stock through Fidelity Brokerage Services LLC on the NYSE, with an indicated aggregate market value of $536,368.18. The filing notes that 57,434,740 shares of Glaukos common stock were outstanding at the time referenced. The shares to be sold were acquired on 12/09/2025 through an option granted on 06/02/2016, with cash as the form of payment. By signing the notice, the seller represents that they are not aware of any undisclosed material adverse information about Glaukos’ current or prospective operations.
GLAUKOS Corp (GKOS) senior executive stock sale disclosed. The company’s Senior Vice President and Chief Financial Officer reported selling 315 shares of common stock on 11/25/2025 at a price of $105 per share. After this transaction, the executive beneficially owns 50,488 shares of GLAUKOS common stock.
The filing notes that these sales were carried out under a Rule 10b5-1 trading plan adopted on June 11, 2025, which is a pre-arranged plan designed to allow insiders to sell stock over time according to set instructions. The reported holdings include 13,751 restricted stock units that have not yet vested or been delivered and 167 stock units acquired through the company’s employee stock purchase plan.
A shareholder of GKOS filed a Form 144 indicating an intent to sell 315 shares of common stock through Fidelity Brokerage Services LLC on the NYSE. The shares have an aggregate market value of 33,075.00 based on the information provided, with the sale targeted for 11/25/2025. These 315 shares came from restricted stock that vested on 04/01/2025 and were received as compensation from the issuer on that date. The filing notes that there were 57,434,740 shares outstanding of the same class of common stock, providing context for the size of this planned sale.
Glaukos Corp (GKOS) reported an insider stock sale by its President & COO. On 11/18/2025, the executive sold 19,340 shares of Glaukos common stock at a price of $90 per share. After this transaction, the reporting person beneficially owns 92,366 shares, which includes 62,605 restricted stock units that have not yet vested or been delivered. The filing notes that the report is made by a single reporting person and is signed by an attorney-in-fact on the insider’s behalf.
Glaukos Corporation (GKOS) reported that an affiliated holder plans to sell 19,340 common shares under Rule 144. The shares will be sold through Fidelity Brokerage Services LLC on or about 11/18/2025 on the NYSE, with an indicated aggregate market value of $1,740,600. The filing notes that 57,434,740 common shares were outstanding. Most of the shares being sold were acquired between March 2023 and April 2024 through restricted stock vesting as compensation, along with a smaller amount purchased through the company’s employee stock purchase plan. The signer represents that they are not aware of undisclosed material adverse information about Glaukos.
Glaukos Corporation announced it intends to use an updated investor presentation, furnished as Exhibit 99.1, in meetings with investors and other stakeholders. The materials are provided under Item 7.01 (Regulation FD) and are available on the company’s investor website at investors.glaukos.com.
The company states the information in Item 7.01 and Exhibit 99.1 is not deemed filed under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly referenced. The exhibit is dated November 2025.